Inovio Pharmaceuticals Inc (INO) Shares Bought by Bank of Montreal Can

Bank of Montreal Can grew its stake in Inovio Pharmaceuticals Inc (NASDAQ:INO) by 15.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 212,108 shares of the biopharmaceutical company’s stock after acquiring an additional 28,400 shares during the period. Bank of Montreal Can’s holdings in Inovio Pharmaceuticals were worth $876,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. BlueCrest Capital Management Ltd acquired a new position in shares of Inovio Pharmaceuticals in the second quarter valued at about $107,000. Virginia Retirement Systems ET AL acquired a new position in shares of Inovio Pharmaceuticals in the third quarter valued at about $101,000. Neuberger Berman Group LLC acquired a new position in shares of Inovio Pharmaceuticals in the third quarter valued at about $115,000. Engineers Gate Manager LP acquired a new position in shares of Inovio Pharmaceuticals in the third quarter valued at about $117,000. Finally, Emerald Advisers Inc. PA grew its stake in shares of Inovio Pharmaceuticals by 84.0% in the third quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 9,280 shares in the last quarter. 32.04% of the stock is currently owned by institutional investors.

INO has been the topic of several research reports. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 25th. Maxim Group set a $12.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. BidaskClub upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. Finally, ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $18.80.

Shares of Inovio Pharmaceuticals Inc (NASDAQ INO) opened at $4.20 on Monday. The stock has a market cap of $379.24, a PE ratio of -3.56 and a beta of 2.54. Inovio Pharmaceuticals Inc has a one year low of $3.76 and a one year high of $9.86.

ILLEGAL ACTIVITY WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/19/inovio-pharmaceuticals-inc-ino-shares-bought-by-bank-of-montreal-can.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals Inc (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply